TIDMONG 
 
RNS Number : 2801L 
Oxford Nutrascience Group PLC 
05 May 2010 
 

 
 
 
5 May 2010 
 
Oxford Nutrascience Group plc 
("Oxford Nutrascience" or "the Company") 
 
Subsidiary results to 31 December 2009 
 
Oxford Nutrascience announces the final results for its wholly owned subsidiary, 
Oxford Nutrascience Ltd ("ONL"), for the period ending 31 December 2009. On 27 
January 2010 Oxford Nutrascience acquired the entire issued share capital of ONL 
pursuant to the terms of the Share Exchange Agreement details of which are set 
out in the admission document dated 8 February 2010. 
 
Oxford Nutrascience  is a UK consumer healthcare company that develops chewy 
confectionery, chewable tablets and liquid suspensions to allow medicines and 
vitamin supplements to be taken in a more pleasant and convenient way. 
 
Oxford Nutrascience's medicine development work is currently focused on pain 
relieving drugs, indigestion preparations and cough and cold medicines. Oxford 
Nutrascience intends to increase its product range and license its intellectual 
property to major brand owners in the over-the-counter (OTC) and prescription 
pharmaceutical sectors. 
 
POST PERIOD HIGHLIGHTS 
·    Successful admission of Oxford Nutrascience to AIM 
·    Development agreement signed to scale-up and validate manufacturing 
processes for Chewitab(TM) 
·    Patent applications submitted 
·    Interest by consumer healthcare pharmaceutical brand owners to license 
technology 
·    Appointment of Marcelo Bravo as Executive Chairman, with responsibility for 
R&D. 
 
Nigel Theobald, Chief Executive, Oxford Nutrascience Group plc said: 
"The IPO of Oxford Nutrascience has given the Company greater visibility amongst 
over the counter healthcare companies looking for more convenient and pleasant 
tasting medicines and supplements that help people who have difficulty 
swallowing pills and tablets. 
 
"We are experiencing increasing interest from potential licensing partners and 
are excited about our plans for the launch of our own branded supplement 
products. 
 
"As Oxford Nutrascience moves into the development phase for our chewitabs and 
suspensions ahead of full scale production, we continue to make advancements of 
our technology to improve taste and performance of our technology. This progress 
has allowed us to strengthen our patent applications." 
 
A copy of the results will also be made available on the Company's website - 
www.oxfordnutrascience.com. 
 
Contacts: 
Oxford Nutrascience Group Plc 
Nigel Theobald, Chief Executive                           +44 1865 854874 
Mark Way, Investor and Media Relations              +44 7786 116991 
 
ZAI Corporate Finance (Nominated Adviser) 
Ray Zimmerman                                                +44 20 7060 2220 
Sarang Shah                                                     +44 20 7060 
2220 
 
 
CHAIRMAN'S STATEMENT 
 
Following the IPO of the Company in February of this year the structure of the 
business changed significantly and consequently the financial results for the 
year ended 2009 have a reduced relevance. 
 
 
We have further developed our technology for the use of prebiotic soluble fibres 
in medicine delivery systems that disperse and solubilise medicines, improve 
taste and mouth feel, simplify processing and eliminate additives. We are now 
well placed to bring new products and delivery systems to market. 
 
Products 
Our products fall into the following two categories: 
 
1)   Chews: We currently produce Ellactiva , a calcium chewy supplement sold in 
the UK and in the Middle East, and plan to launch new chews to complement this 
existing product. 
 
2)   Chewable tablets and liquid suspensions: The target market for Oxford 
Nutrasciences' Chewitabs(TM) and liquid suspension delivery systems are 
supplements, over-the-counter ("OTC") pain relieving drugs, indigestion 
preparations and cough and cold medicines. 
 
The successful IPO and listing of the Company 
The IPO of Oxford Nutrascience earlier this year has allowed the Company to 
accelerate its strategy of making self medication easier and more pleasant by 
increasing its product range. The IPO has also allowed us to initiate and 
advance discussions with major brand owners in the OTC and prescription 
pharmaceutical sectors for the licensing of our intellectual property. 
 
The Company raised GBP1.1 million, before expenses, via a placing of 62,857,148 
ordinary shares of 0.1p each at a price of 1.75p per share. 
 
The net proceeds of the Placing will be used primarily to provide funds needed 
by the Group to develop and grow the existing business including the launch of 
our own chews and provide funding for further development of the Company's 
technology. 
 
Marcelo Bravo, Chairman 
 
STATEMENT OF COMPREHENSIVE INCOME 
For the year ended 31 December 2009 
 
 
+--------------------------------------+-------+-----------+-----------+ 
|                                      |Notes  |   Year to | (restated | 
|                                      |       |           | - note 1) | 
|                                      |       |        31 | Period to | 
|                                      |       |  December |        31 | 
|                                      |       |      2009 |  December | 
|                                      |       |           |      2008 | 
+--------------------------------------+-------+-----------+-----------+ 
|                                      |       |       GBP |       GBP | 
+--------------------------------------+-------+-----------+-----------+ 
| Revenue                              |  2    |    54,293 |    42,677 | 
+--------------------------------------+-------+-----------+-----------+ 
| Cost of sales                        |       |  (32,044) |  (31,582) | 
+--------------------------------------+-------+-----------+-----------+ 
| Gross profit                         |       |    22,249 |    11,095 | 
+--------------------------------------+-------+-----------+-----------+ 
| Administrative expenses              |  3    | (262,767) | (131,133) | 
+--------------------------------------+-------+-----------+-----------+ 
| Operating loss                       |  3    | (240,518) | (120,038) | 
+--------------------------------------+-------+-----------+-----------+ 
| Finance Income                       |  6    |    11,356 |    13,520 | 
+--------------------------------------+-------+-----------+-----------+ 
| Loss before taxation                 |       | (229,162) | (106,518) | 
+--------------------------------------+-------+-----------+-----------+ 
| Taxation                             |  7    |         - |         - | 
+--------------------------------------+-------+-----------+-----------+ 
| Loss for the Year                    |       | (229,162) | (106,518) | 
+--------------------------------------+-------+-----------+-----------+ 
| Other comprehensive income for the   |       |         - |         - | 
| period, net of tax                   |       |           |           | 
+--------------------------------------+-------+-----------+-----------+ 
| Total comprehensive income for the   |       | (229,162) | (106,518) | 
| period                               |       |           |           | 
+--------------------------------------+-------+-----------+-----------+ 
| Attributable to:                     |       |           |           | 
+--------------------------------------+-------+-----------+-----------+ 
| Equity holders of the Company        |       | (229,162) | (106,518) | 
+--------------------------------------+-------+-----------+-----------+ 
 
Comparative figures comprise the period from incorporation on 8 February 2008 to 
31 December 2008. 
 
The loss for the year arises from the Company's continuing operations. 
 
 
STATEMENT OF CHANGES IN EQUITY 
For the period ended 31 December 2009 
 
 
+-----------------+---------+----------+---------+-----------+-----------+ 
|                 |        Attributable to the equity holders of         | 
|                 |                     the Company                      | 
+-----------------+------------------------------------------------------+ 
|                 |   Share |    Share |   Share | (restated |     Total | 
|                 | Capital |  Premium |   Based | - note 1) |    Equity | 
|                 |         |          | Payment |  Retained |           | 
|                 |         |          | Reserve |   Deficit |           | 
+-----------------+---------+----------+---------+-----------+-----------+ 
|                 |     GBP |      GBP |     GBP |       GBP |       GBP | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| As at 8         |       - |        - |       - |         - |         - | 
| February 2008   |         |          |         |           |           | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| Loss for the    |       - |        - |       - | (106,518) | (106,518) | 
| period          |         |          |         |           |           | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| Issue of shares | 130,767 |  984,533 |       - |         - | 1,115,300 | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| As at 31        | 130,767 |  984,533 |       - | (106,518) | 1,008,782 | 
| December 2008   |         |          |         |           |           | 
| (restated)      |         |          |         |           |           | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| Loss for the    |       - |        - |       - | (229,162) | (229,162) | 
| year            |         |          |         |           |           | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| Issue of shares |  29,700 | (29,700) |       - |         - |         - | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| Share based     |       - |        - |  15,915 |         - |    15,915 | 
| payment         |         |          |         |           |           | 
+-----------------+---------+----------+---------+-----------+-----------+ 
| As at 31        | 160,467 |  954,833 |  15,915 | (335,680) |   795,535 | 
| December 2009   |         |          |         |           |           | 
+-----------------+---------+----------+---------+-----------+-----------+ 
 
 
STATEMENT OF FINANCIAL POSITION 
As at 31 December 2009 
 
 
+----------------------------------------+-------+-----------+-----------+ 
|                                        |Notes  |      2009 | (restated | 
|                                        |       |           | - note 1) | 
|                                        |       |           |      2008 | 
+----------------------------------------+-------+-----------+-----------+ 
|                                        |       |       GBP |       GBP | 
+----------------------------------------+-------+-----------+-----------+ 
| Assets                                 |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Non-current assets                     |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Property, plant and equipment          |  8    |       718 |         - | 
+----------------------------------------+-------+-----------+-----------+ 
| Intangible assets                      |  9    |     7,695 |     1,046 | 
+----------------------------------------+-------+-----------+-----------+ 
|                                        |       |     8,413 |     1,046 | 
+----------------------------------------+-------+-----------+-----------+ 
| Current assets                         |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Inventories                            |  10   |    38,896 |    19,175 | 
+----------------------------------------+-------+-----------+-----------+ 
| Trade and other receivables            |  11   |   169,442 |    40,202 | 
+----------------------------------------+-------+-----------+-----------+ 
| Cash and cash equivalents              |  12   |   637,725 |   988,967 | 
+----------------------------------------+-------+-----------+-----------+ 
|                                        |       |   846,063 | 1,048,344 | 
+----------------------------------------+-------+-----------+-----------+ 
| Total assets                           |       |   854,476 | 1,049,390 | 
+----------------------------------------+-------+-----------+-----------+ 
|                                        |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Liabilities                            |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Current liabilities                    |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Trade and other payables               |  13   |  (58,941) |  (40,608) | 
+----------------------------------------+-------+-----------+-----------+ 
| Total liabilities                      |       |  (58,941) |  (40,608) | 
+----------------------------------------+-------+-----------+-----------+ 
|                                        |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Net assets                             |       |   795,535 | 1,008,782 | 
+----------------------------------------+-------+-----------+-----------+ 
|                                        |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Equity                                 |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Attributable to equity holders of the  |       |           |           | 
| Company                                |       |           |           | 
+----------------------------------------+-------+-----------+-----------+ 
| Share capital                          |  14   |   160,467 |   130,767 | 
+----------------------------------------+-------+-----------+-----------+ 
| Share premium                          |  15   |   954,833 |   984,533 | 
+----------------------------------------+-------+-----------+-----------+ 
| Share based payment reserve            |  5    |    15,915 |         - | 
+----------------------------------------+-------+-----------+-----------+ 
| Retained deficit                       |       | (335,680) | (106,518) | 
+----------------------------------------+-------+-----------+-----------+ 
| Net equity                             |       |   795,535 | 1,008,782 | 
+----------------------------------------+-------+-----------+-----------+ 
 
These financial statements have been prepared in accordance with the special 
provisions for small companies under Part 15 of the Companies Act 2006. 
 
Approved by the board of Directors and authorised for issue on 14 April 2010 and 
signed on its behalf by: 
 
 
Nigel Theobald 
Director 
 
Company number: 06498279 
 
 
STATEMENT OF CASH FLOWS 
For the year ended 31 December 2009 
 
 
+----------------------------------------+--------+-----------+-----------+ 
|                                        | Notes  |      Year | (restated | 
|                                        |        |     to 31 | - note 1) | 
|                                        |        |  December | Period to | 
|                                        |        |      2009 |        31 | 
|                                        |        |           |  December | 
|                                        |        |           |      2008 | 
+----------------------------------------+--------+-----------+-----------+ 
|                                        |        |       GBP |       GBP | 
+----------------------------------------+--------+-----------+-----------+ 
| Operating activities                   |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Loss before tax                        |        | (229,162) | (106,518) | 
+----------------------------------------+--------+-----------+-----------+ 
| Adjustments for non-cash items:        |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Share based payment                    |   5    |    15,915 |         - | 
+----------------------------------------+--------+-----------+-----------+ 
| Depreciation of property, plant and    |   8    |        20 |         - | 
| equipment                              |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Amortisation of intangible assets      |   9    |       868 |       116 | 
+----------------------------------------+--------+-----------+-----------+ 
| Increase in inventories                |        |  (19,721) |  (19,175) | 
+----------------------------------------+--------+-----------+-----------+ 
| Increase in trade and other            |        | (129,240) |  (40,202) | 
| receivables                            |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Increase in trade and other payables   |        |    18,333 |    40,608 | 
+----------------------------------------+--------+-----------+-----------+ 
| Finance income                         |        |  (11,356) |  (13,520) | 
+----------------------------------------+--------+-----------+-----------+ 
| Net cash outflow from operations       |        | (354,343) | (138,691) | 
+----------------------------------------+--------+-----------+-----------+ 
|                                        |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Investing activities                   |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Purchase of property, plant and        |   8    |     (738) |         - | 
| equipment                              |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Purchase of intangible assets          |   9    |   (7,517) |   (1,162) | 
+----------------------------------------+--------+-----------+-----------+ 
| Interest received                      |        |    11,356 |    13,520 | 
+----------------------------------------+--------+-----------+-----------+ 
| Net cash inflow from investing         |        |     3,101 |    12,358 | 
| activities                             |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
|                                        |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Financing activities                   |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Proceeds from issue of share capital   |14, 15  |         - | 1,115,300 | 
+----------------------------------------+--------+-----------+-----------+ 
| Net cash inflow from financing         |        |         - | 1,115,300 | 
| activities                             |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
|                                        |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| (Decrease)/increase in cash and cash   |        | (351,242) |   988,967 | 
| equivalents                            |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Cash and cash equivalents at start of  |        |   988,967 |         - | 
| period                                 |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
| Cash and cash equivalents at end of    |  19    |   637,725 |   988,967 | 
| period                                 |        |           |           | 
+----------------------------------------+--------+-----------+-----------+ 
Comparative figures comprise the period from incorporation on 8 February 2008 to 
31 December 2008. 
 
 
NOTE TO THE FINANCIALINFORMATION 
For the year ended 31 December 2009 
 
 
 
1) ACCOUNTING POLICIES 
 
The Company has adopted International Financial Reporting Standards ("IFRS") 
with effect from 8 February 2008 and as such, these are the Company's first set 
of annual financial statements prepared in accordance with IFRS.  Previously, 
the Company prepared its financial statements in accordance with accounting 
standards generally accepted in the United Kingdom ("UK GAAP").  The transition 
date to IFRS is 8 February 2008. 
 
BASIS OF ACCOUNTING 
The financial information have been prepared under the historical cost 
convention in accordance with International Financial Reporting Standards 
("IFRS") and International Accounting Standards as issued by the International 
Accounting Standards Board ("IASB") as well as interpretations issued by the 
International Financial Reporting Interpretations Committee ("IFRIC") as adopted 
by the European Union. 
 
The company has presented income and expenses in one statement, a statement of 
comprehensive income, which is separate from owner changes in equity, as 
required by IAS 1.  Components of other comprehensive income, being items of 
income and expense not recognised in profit or loss as permitted by other IFRS, 
are also displayed in the statement of comprehensive income. 
 
Historical Cost Convention 
The financial information has been prepared on the historic cost basis.  The 
principal accounting policies applied are set out below. 
 
Prior period adjustment 
The 2008 comparative figures have been restated to adjust for matters identified 
and corrected during the preparation of the financial information for inclusion 
in the AIM listing Admission Document as part of the AIM listing process 
referred to in the Post Balance Sheet Events , see note 18.  Prior period 
adjustments have been made as follows: 
 
·      Other operating income has been reduced by GBP100; 
·      Finance income has been increased by GBP3,793 to GBP13,520 to include 
deferred interest; 
·      The deferred tax asset of GBP23,000 has been reversed as the Directors 
consider it to be too early to determine whether or not the losses are 
recoverable; and 
·      Reclassification between share capital and share premium has been 
amended. 
 
The consequence of the above adjustments has been to increase loss after tax by 
GBP19,307 to GBP106,518, and to decrease total equity from GBP1,028,089 to 
GBP1,008,782. 
 
SEGMENTAL REPORTING 
The reportable disclosures are identified by the chief operating decision maker 
by the way management has organised the firm. The firm operates out of one 
location and produces one product. 
 
The chief operating decision maker reviews the performance of the Company based 
on total revenues and costs and not by any segmental reporting. 
 
REVENUE 
Revenue comprises the fair value of the consideration received or receivable for 
the sale of goods in the normal course of business, net of discounts, VAT and 
other sales related taxes and is recognised to the extent that it is probable 
that the economic benefits associated with the transaction will flow in to the 
Company. 
 
Grant income is recognised as earned based on contractual conditions, generally 
as expenses are incurred, or in the case of capital expenditure grants, as the 
equipment purchased is used over the life of the grant. 
 
FOREIGN CURRENCIES 
Transactions in foreign currencies are initially recorded at the rates of 
exchange prevailing on the dates of the transactions. At each balance sheet 
date, monetary assets and liabilities that are denominated in foreign currencies 
are retranslated at the rates prevailing on the balance sheet date.   Gains and 
losses arising on retranslation are charged to profit or loss as they are 
incurred. 
The functional and presentational currency of the Company is British pounds. 
 
RESEARCH AND DEVELOPMENT 
Research costs are charged to the statement of comprehensive income as they are 
incurred.  Development costs that meet the criteria below are capitalised as 
intangible assets when it is probable that the future economic benefits will 
flow to the Company.  Such intangible assets are amortised on a straight-line 
basis from the point at which the assets are ready for use over the period of 
the expected benefit, and are reviewed for an indication of impairment at each 
balance sheet date.  Other development costs are charged against profit or loss 
as incurred since the criteria for their recognition as an asset are not met. 
 
The criteria for recognising expenditure as an asset are: 
 
·      it is technically feasible to complete the product; 
·      management intends to complete the product and use or sell it; 
·      there is an ability to use or sell the product; 
·      it can be demonstrated how the product will generate probable future 
economic benefits; 
·      adequate technical, financial and other resources are available to 
complete the development, use or sell the product; and 
·      expenditure attributable to the product can be reliably measured. 
 
The costs of an internally generated intangible asset comprise all directly 
attributable costs necessary to create, produce and prepare the asset to be 
capable of operating in the manner intended by management.  Directly 
attributable costs include employee costs incurred on technical development, 
testing and certification, materials consumed and any relevant third party cost. 
 The costs of internally generated developments are recognised as intangible 
assets and are subsequently measured in the same way as externally acquired 
intangible assets.  However, until completion of the development project, the 
assets are subject to impairment testing only. 
 
No research and development costs have been capitalised to 31 December 2009 
since the criteria for their recognition as an asset has not been met. 
LEASES 
Rental payable under operating leases, which are leases where the lessor retains 
a significant proportion of the risks and benefits of the asset, are charged in 
the statement of comprehensive income on a straight line basis over the expected 
lease term. 
 
PROPERTY, PLANT AND EQUIPMENT 
Property, plant and equipment are stated at historical cost less accumulated 
depreciation.  The cost of property, plant and equipment is their purchase 
price, together with any directly attributable costs of acquisition. 
 
Depreciation is provided on all property, plant and equipment assets at rates 
calculated to write each asset down to its estimated residual value evenly over 
its expected useful life, as follows: 
 
Computer equipment:                                                         over 
3 years 
 
INTANGIBLE ASSETS 
Patent costs and trademarks are stated at historic cost net of amortisation and 
any provision for impairment.  Patent costs and trademarks are amortised over 
their useful economic life of 10 years years on a straight line basis. 
Amortisation is included within Administrative Expenses in the Statement of 
Comprehensive Income. 
 
IMPAIRMENT OF PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS 
At each balance sheet date, the Company reviews the carrying amounts of its 
property, plant and equipment and intangible assets to determine whether there 
is any indication that those assets have suffered an impairment loss. If any 
such indication exists, the recoverable amount of the asset is estimated in 
order to determine the extent of the impairment loss (if any). 
 
Discounted cash flow valuation techniques are generally applied for assessing 
recoverable amounts using three year forward looking cash flow projections and 
terminal value estimates, together with discount rates appropriate to the risk 
of the related cash generating units. 
 
The recoverable amount of the intangible asset is the higher of its value in use 
and its fair value less costs to sell.  Discounted cash flows are used to 
calculate the recoverable amounts which are based on cash generating units where 
assets do not generate cash flows independent from other assets. 
 
If the recoverable amount of an asset is estimated to be less than its carrying 
amount, the carrying amount of the asset is reduced to its recoverable amount. 
An impairment loss is recognised as an expense immediately. 
 
FINANCIAL ASSETS AND LIABILITIES 
 
Trade and other receivables 
Trade and other receivables do not carry any interest and are initially 
recognised at fair value. They are subsequently measured at amortised cost using 
the effective interest rate method, less any provision for impairment. 
 
Impairment provisions are recognised when there is objective evidence that the 
Company will be unable to collect all of the amounts due under the terms 
receivable, the amount of such a provision being the difference between the net 
carrying amount and the present value of the future expected cash flows 
associated with the impaired receivable. 
 
Inventories 
Inventories are stated at the lower of cost and net realisable value.  Cost 
includes all costs incurred in bringing each product to its present location and 
condition.   Net realisable value is based on estimated selling price less any 
further costs expected to be incurred to disposal.  Cost is determined using the 
first in first out method of valuation.  Provision is made for slow moving or 
obsolete items. 
 
Trade and other payables 
Trade and other payables are not interest bearing and are initially recognised 
at fair value. They are subsequently measured at amortised cost using the 
effective interest method. 
 
Cash and cash equivalents 
Cash and cash equivalents comprise cash at hand and deposits on a term of not 
greater than 3 months. 
 
Share capital 
Ordinary shares are classified as equity.  Incremental costs directly 
attributable to the issue of new shares or options are shown in equity as a 
deduction, net of tax from proceeds. 
 
SHARE BASED PAYMENTS 
The Company undertakes equity settled share-based payment transactions with 
certain employees. 
 
Equity settled share-based payment transactions are measured with reference to 
the fair value at the date of grant, recognised on a straight line basis over 
the vesting period, based on the company's estimate of shares that will 
eventually vest.  Fair value is measured using the Black-Scholes model. 
 
At each balance sheet date before vesting, the cumulative expense is calculated, 
representing the extent to which the vesting period has expired and management's 
best estimate of the achievement or otherwise of non-market conditions and the 
number of equity instruments that will ultimately vest.  The movement in 
cumulative expense since the previous balance sheet date is recognised in the 
statement of comprehensive income, with a corresponding entry in equity. 
 
TAXATION 
The tax expense represents the sum of the tax currently payable and deferred 
tax. 
The tax currently payable is based on taxable profit for the period. The 
Company's liability for current tax is calculated by using tax rates that have 
been enacted or substantively enacted by the balance sheet date. 
Deferred tax is the tax expected to be payable or recoverable on differences 
between the carrying amount of assets and liabilities in the financial 
information and the corresponding tax bases used in the computation of taxable 
profit, and is accounted for using the balance sheet liability method. 
Deferred tax liabilities are recognised for all taxable temporary differences 
and deferred tax assets are recognised to the extent that it is probable that 
taxable profits will be available against which deductible temporary differences 
can be utilised. Deferred tax is calculated at the tax rates that are expected 
to apply to the period when the asset is realised or the liability is settled 
using tax rates that have been enacted or substantively enacted by the balance 
sheet date. Deferred tax is charged or credited to profit or loss, except when 
it relates to items credited or charged directly to equity, in which case the 
deferred tax is also dealt with in equity. 
 
CRITICAL ACCOUNTING ESTIMATES AND AREAS OF JUDGEMENT 
Estimates and judgements are continually evaluated and are based on historical 
experience and other factors, including expectations of future events that are 
believed to be reasonable under the circumstances. Actual results may differ 
from these estimates. The estimates and assumptions that have the most 
significant effects on the carrying amounts of the assets and liabilities in the 
financial information are discussed below: 
 
Equity settled share-based payments 
The estimation of share-based payment costs requires the selection of an 
appropriate valuation method, consideration as to the inputs necessary for the 
valuation model chosen and the estimation of the number of awards that will 
ultimately vest, inputs for which arise from judgements relating to the future 
volatility of the share price of comparable companies, the Company's expected 
dividend yields, risk free interest rates and expected lives of the options. The 
Directors draw on a variety of sources to aid in the determination of the 
appropriate data to use in such calculations. 
 
Research and development costs 
Careful judgement by the Directors is applied when deciding whether the 
recognition requirements for capitalising development costs have been met.  This 
is necessary as the economic success of any product development is uncertain and 
may be subject to future technical problems.  Judgements are based on the 
information available at each Balance Sheet date which includes the progress 
with testing and certification and progress on, for example, establishment of 
commercial arrangements with third parties.  In addition, all internal 
activities related to research and development of new products are continuously 
monitored by the Directors. 
 
ACCOUNTING STANDARDS AND INTERPRETATIONS NOT APPLIED 
At the date of authorisation of the financial information, the following 
Standards and Interpretations relevant to the operations of the Company, which 
have not yet been applied in this financial information, were in issue but not 
yet effective: 
 
+------+-----------------------------------------+------------+ 
|      |                                         | Effective  | 
|      |                                         | for        | 
|      |                                         | periods    | 
|      |                                         | commencing | 
|      |                                         | on or      | 
|      |                                         | after      | 
+------+-----------------------------------------+------------+ 
| IFRS | Share based payments (amendments)       | 1 January  | 
| 2    |                                         | 2010       | 
+------+-----------------------------------------+------------+ 
| IFRS | Business combination (revision)         | 1 July     | 
| 3    |                                         | 2009       | 
+------+-----------------------------------------+------------+ 
| IFRS | Operating segments (amendments)         | 1 January  | 
| 8    |                                         | 2010       | 
+------+-----------------------------------------+------------+ 
| IAS  | Presentation of financial statements    | 1 January  | 
| 1    | (amendments)                            | 2010       | 
+------+-----------------------------------------+------------+ 
| IAS  | Statement of Cash Flows (amendments)    | 1 January  | 
| 7    |                                         | 2010       | 
+------+-----------------------------------------+------------+ 
| IAS  | Leases (amendments)                     | 1 January  | 
| 17   |                                         | 2010       | 
+------+-----------------------------------------+------------+ 
| IAS  | Consolidated and Separate Financial     | 1 July     | 
| 27   | Statements (amendments)                 | 2009       | 
+------+-----------------------------------------+------------+ 
| IAS  | Financial Instruments: Presentation     | 1          | 
| 32   | (amendments)                            | February   | 
|      |                                         | 2010       | 
+------+-----------------------------------------+------------+ 
| IAS  | Impairment of Assets (amendments)       | 1 January  | 
| 36   |                                         | 2010       | 
+------+-----------------------------------------+------------+ 
| IAS  | Intangible Assets (amendments)          | 1 July     | 
| 38   |                                         | 2009       | 
+------+-----------------------------------------+------------+ 
| IAS  | Financial Instruments: Recognition and  | 1 July     | 
| 39   | Measurement (amendments)                | 2009       | 
+------+-----------------------------------------+------------+ 
 
The Directors do not anticipate that the adoption of these Standards and 
Interpretations will have a material impact on the financial information of the 
Company. 
 
2)  SEGMENTAL REPORTING 
 
The chief operating decision maker is Nigel Theobald who reviews the reports of 
the Company as one segment only. The review of the Company's operating results 
is not broken down into other segments. 
 
Revenue represents amounts derived from the sale of products which fall within 
the Company's ordinary activities after taking deduction of trade discounts and 
Value Added Tax.  The Company's revenue is solely attributable to the sale of a 
calcium chew supplement, Ellactiva and to grant income.  The Ellactiva revenues 
were generated in two main geographic areas, based on the customer's location, 
although all are managed in the UK.  The Company's revenue per customer 
orientation is as follows: 
 
+-----------------------------------------+----------+----------+ 
|                                         |  Year to |   Period | 
|                                         |       31 |    to 31 | 
|                                         | December | December | 
|                                         |     2009 |     2008 | 
+-----------------------------------------+----------+----------+ 
| Continuing operations                   |      GBP |      GBP | 
+-----------------------------------------+----------+----------+ 
| Product sales:                          |          |          | 
+-----------------------------------------+----------+----------+ 
| UK*                                     |   35,224 |   22,830 | 
+-----------------------------------------+----------+----------+ 
| Middle East**                           |    9,069 |   19,847 | 
+-----------------------------------------+----------+----------+ 
|                                         |   44,293 |   42,677 | 
+-----------------------------------------+----------+----------+ 
| Grant income                            |   10,000 |        - | 
+-----------------------------------------+----------+----------+ 
| Total Revenue                           |   54,293 |   42,677 | 
+-----------------------------------------+----------+----------+ 
*97% of the UK revenue is generated from one customer (period to 31 December 
2008: 99%) 
** 100% of the Middle East revenue is generated from one customer (period to 31 
December 2008: 100%) 
 
All the Company's assets are held in the UK and all of its capital expenditure 
arises in the UK. 
 
3)  LOSS FROM OPERATIONS 
 
+-----------------------------------------+----------+----------+ 
|                                         |     Year |   Period | 
|                                         |    to 31 |    to 31 | 
|                                         | December | December | 
|                                         |     2009 |     2008 | 
+-----------------------------------------+----------+----------+ 
|                                         |      GBP |      GBP | 
+-----------------------------------------+----------+----------+ 
| Loss from operations is stated after    |          |          | 
| charging to administrative expenses:    |          |          | 
+-----------------------------------------+----------+----------+ 
| Depreciation of property, plant and     |       20 |        - | 
| equipment (see note 8)                  |          |          | 
+-----------------------------------------+----------+----------+ 
| Amortisation of intangible assets (see  |      868 |      116 | 
| note 9)                                 |          |          | 
+-----------------------------------------+----------+----------+ 
| Other operating lease rentals           |    3,275 |    4,090 | 
+-----------------------------------------+----------+----------+ 
| Staff costs (see note 4)                |  116,713 |   63,521 | 
|                                         |          |          | 
+-----------------------------------------+----------+----------+ 
| Foreign exchange losses                 |        - |      266 | 
+-----------------------------------------+----------+----------+ 
| Research and development                |   70,750 |   35,314 | 
+-----------------------------------------+----------+----------+ 
| Auditors remuneration:                  |          |          | 
+-----------------------------------------+----------+----------+ 
| Fees payable to the Company's auditor   |    5,000 |          | 
| for the audit of the Company's accounts |          |        - | 
|                                         |          |          | 
+-----------------------------------------+----------+----------+ 
4)  STAFF COSTS 
 
 
 
+--------------------------------------------+----------+----------+ 
|                                            |  Year to |   Period | 
|                                            |       31 |    to 31 | 
|                                            | December | December | 
|                                            |     2009 |     2008 | 
+--------------------------------------------+----------+----------+ 
|                                            |   Number |   Number | 
+--------------------------------------------+----------+----------+ 
| The average monthly number of persons      |          |          | 
| (including directors) employed by the      |          |          | 
| Company during the period was:             |          |          | 
+--------------------------------------------+----------+----------+ 
| Administration and management              |        2 |        3 | 
+--------------------------------------------+----------+----------+ 
|                                            |          |          | 
+--------------------------------------------+----------+----------+ 
|                                            |  Year to |   Period | 
|                                            |       31 |    to 31 | 
|                                            | December | December | 
|                                            |     2009 |     2008 | 
+--------------------------------------------+----------+----------+ 
|                                            |      GBP |      GBP | 
+--------------------------------------------+----------+----------+ 
| The aggregate remuneration, including      |          |          | 
| directors, comprised:                      |          |          | 
+--------------------------------------------+----------+----------+ 
| Wages and salaries                         |   90,000 |   56,875 | 
+--------------------------------------------+----------+----------+ 
| Social security costs                      |   10,798 |    6,646 | 
+--------------------------------------------+----------+----------+ 
| Share based payments                       |   15,915 |        - | 
+--------------------------------------------+----------+----------+ 
|                                            |  116,713 |   63,521 | 
+--------------------------------------------+----------+----------+ 
 
5)  SHARE BASED PAYMENTS 
 
The Company operates a share option plan, under which certain directors have 
been granted options to subscribe for ordinary shares. All options are equity 
settled. The options have an exercise price of 40p and the vesting period was 
generally 1 or 3 years. If the options remain unexercised after a period of 10 
years from the date of grant, the options expire. The Group has no legal or 
constructive obligation to repurchase or settle the options in cash.  The number 
and weighted average exercise prices of share options are as follows: 
 
+-----------------------------------------+---------+----------+ 
|                                         |  Number | Weighted | 
|                                         |      of |  average | 
|                                         |   share | exercise | 
|                                         | options |    price | 
|                                         |         |      per | 
|                                         |         |    share | 
|                                         |         |  (pence) | 
+-----------------------------------------+---------+----------+ 
|                                         |    2009 |     2009 | 
+-----------------------------------------+---------+----------+ 
| At 8 February 2008 and 31 December 2008 |       - |        - | 
+-----------------------------------------+---------+----------+ 
| Granted during the period               | 300,000 |       40 | 
+-----------------------------------------+---------+----------+ 
| Outstanding at 31 December 2009         | 300,000 |       40 | 
+-----------------------------------------+---------+----------+ 
 
There were no share options outstanding at 31 December 2009 which were eligible 
to be exercised.  To date no share options have been exercised, lapsed or 
forfeited.  There are no market based vesting conditions attached to any of the 
share options outstanding at 31 December 2009. 
 
On 27 January 2010, as part of a re-organisation and AIM listing as set out in 
note 18, the entire issued and to be issued share capital was acquired by Oxford 
Nutrascience Group plc.  The share options have been cancelled and re-issued 
under the same terms within Oxford Nutrascience Group plc. 
 
The fair value of services received in return for share options granted is 
measured by reference to the fair value of the share options granted.  This is 
estimated based on the Black Scholes model which is considered most appropriate 
considering the effects of the vesting conditions, expected exercise price and 
the payment of the dividends by the Company.  The following table lists the 
inputs to the model used for the year ended 31 December 2009, market conditions 
are assumed to be met during the vesting period: 
 
+----------------------------------------------------+----------+ 
|                                                    |  Granted | 
|                                                    |  year to | 
|                                                    |       31 | 
|                                                    | December | 
|                                                    |     2009 | 
+----------------------------------------------------+----------+ 
| Dividend yield                                     |        - | 
+----------------------------------------------------+----------+ 
| Expected volatility*                               |      50% | 
+----------------------------------------------------+----------+ 
| Risk free interest rate                            |     0.5% | 
+----------------------------------------------------+----------+ 
| Expected vesting life of options                   |      1-3 | 
|                                                    |    years | 
+----------------------------------------------------+----------+ 
| Weighted average exercise price                    |      40p | 
+----------------------------------------------------+----------+ 
| Weighted average share price at date of grant      |      40p | 
+----------------------------------------------------+----------+ 
*expected volatility is based on the rate used by similar start-up technology 
companies 
 
A charge has been recognised in the statement of comprehensive income of 
GBP15,915 for the year (period to 31 December 2008: GBPnil). 
 
6) FINANCE INCOME 
+--------------------------------------------+----------+----------+ 
|                                            |     Year |   Period | 
|                                            |    to 31 |    to 31 | 
|                                            | December | December | 
|                                            |     2009 |     2008 | 
+--------------------------------------------+----------+----------+ 
|                                            |      GBP |      GBP | 
+--------------------------------------------+----------+----------+ 
| Bank interest receivable                   |   11,356 |   13,520 | 
+--------------------------------------------+----------+----------+ 
 
7)  TAXATION 
 
 
 
+--------------------------------------------+----------+----------+ 
|                                            |     Year |   Period | 
|                                            |    to 31 |    to 31 | 
|                                            | December | December | 
|                                            |     2009 |     2008 | 
+--------------------------------------------+----------+----------+ 
|                                            |      GBP |      GBP | 
+--------------------------------------------+----------+----------+ 
| Current tax:                               |          |          | 
+--------------------------------------------+----------+----------+ 
| UK corporation tax on losses of period     |        - |        - | 
|                                            |          |          | 
+--------------------------------------------+----------+----------+ 
|                                            |          |          | 
+--------------------------------------------+----------+----------+ 
| Deferred tax:                              |          |          | 
+--------------------------------------------+----------+----------+ 
| Origination and reversal of timing         |        - |        - | 
| differences                                |          |          | 
+--------------------------------------------+----------+----------+ 
|                                            |          |          | 
+--------------------------------------------+----------+----------+ 
| Tax on loss on ordinary activities         |        - |        - | 
+--------------------------------------------+----------+----------+ 
 
The charge for the period can be reconciled to the loss before tax per the 
Statement of Comprehensive Income as follows: 
 
+--------------------------------------------+-----------+-----------+ 
|                                            |      Year | (restated | 
|                                            |     to 31 | - note 1) | 
|                                            |  December | Period to | 
|                                            |      2009 |        31 | 
|                                            |           |  December | 
|                                            |           |      2008 | 
+--------------------------------------------+-----------+-----------+ 
|                                            |       GBP |       GBP | 
+--------------------------------------------+-----------+-----------+ 
| The tax assessed for the Year varies from  |           |           | 
| the small company rate of corporation tax  |           |           | 
| as explained below:                        |           |           | 
+--------------------------------------------+-----------+-----------+ 
| Loss on ordinary activities before tax     | (229,162) | (106,518) | 
|                                            |           |           | 
+--------------------------------------------+-----------+-----------+ 
| Tax at the standard rate of corporation    |  (48,124) |  (22,156) | 
| tax 21.0% (2008:20.8%)                     |           |           | 
+--------------------------------------------+-----------+-----------+ 
|                                            |           |           | 
+--------------------------------------------+-----------+-----------+ 
| Effects of:                                |           |           | 
+--------------------------------------------+-----------+-----------+ 
| Expenses not deductable for tax purposes   |       186 |        80 | 
|                                            |           |           | 
+--------------------------------------------+-----------+-----------+ 
| Online filing tax incentive                |      (16) |      (21) | 
+--------------------------------------------+-----------+-----------+ 
| Unutilised tax losses                      |    47,954 |    22,316 | 
|                                            |           |           | 
+--------------------------------------------+-----------+-----------+ 
| Change in UK corporation tax rate          |         - |     (219) | 
+--------------------------------------------+-----------+-----------+ 
| Tax charge for the period                  |         - |         - | 
+--------------------------------------------+-----------+-----------+ 
 
The Company has estimated losses of GBP335,682 (2008: loss of GBP106,518) 
available for carry forward against future trading profit.  The Company has not 
recognised a deferred tax asset of GBP70,270 relating to these losses as their 
recoverability is uncertain (2008: GBP22,316). 
 
8)  PROPERTY, PLANT AND EQUIPMENT 
 
+-------------------------------------------+---------+--------+ 
|                                           |         |  Total | 
+-------------------------------------------+---------+--------+ 
|                                           |         |    GBP | 
+-------------------------------------------+---------+--------+ 
| Cost                                      |         |        | 
+-------------------------------------------+---------+--------+ 
| At 8 February 2008 and 31 December 2008   |         |      - | 
+-------------------------------------------+---------+--------+ 
| Additions                                 |         |    738 | 
+-------------------------------------------+---------+--------+ 
| At 31 December 2009                       |         |    738 | 
+-------------------------------------------+---------+--------+ 
|                                           |         |        | 
| Depreciation                              |         |        | 
+-------------------------------------------+---------+--------+ 
| At 8 February 2008 and 31 December 2008   |         |      - | 
+-------------------------------------------+---------+--------+ 
| Charge for the year                       |         |     20 | 
+-------------------------------------------+---------+--------+ 
| At 31 December 2009                       |         |     20 | 
+-------------------------------------------+---------+--------+ 
|                                           |         |        | 
+-------------------------------------------+---------+--------+ 
| Net book value                            |         |        | 
+-------------------------------------------+---------+--------+ 
| At 31 December 2009                       |         |    718 | 
+-------------------------------------------+---------+--------+ 
| At 31 December 2008                       |         |      - | 
+-------------------------------------------+---------+--------+ 
| At 8 February 2008                        |         |      - | 
+-------------------------------------------+---------+--------+ 
 
9)  INTANGIBLE ASSETS 
 
+-------------------------------------------+---------+------------+ 
|                                           |         |    Patents | 
|                                           |         |          & | 
|                                           |         | trademarks | 
+-------------------------------------------+---------+------------+ 
|                                           |         |        GBP | 
+-------------------------------------------+---------+------------+ 
| Cost                                      |         |            | 
+-------------------------------------------+---------+------------+ 
| At 8 February 2008                        |         |          - | 
+-------------------------------------------+---------+------------+ 
| Additions                                 |         |      1,162 | 
+-------------------------------------------+---------+------------+ 
| At 31 December 2008                       |         |      1,162 | 
+-------------------------------------------+---------+------------+ 
| Additions                                 |         |      7,517 | 
+-------------------------------------------+---------+------------+ 
| At 31 December 2009                       |         |      8,679 | 
+-------------------------------------------+---------+------------+ 
|                                           |         |            | 
| Amortisation                              |         |            | 
+-------------------------------------------+---------+------------+ 
| At 8 February 2008                        |         |          - | 
+-------------------------------------------+---------+------------+ 
| Charge for the period                     |         |        116 | 
+-------------------------------------------+---------+------------+ 
| At 31 December 2008                       |         |        116 | 
+-------------------------------------------+---------+------------+ 
| Charge for the year                       |         |        868 | 
+-------------------------------------------+---------+------------+ 
| At 31 December 2009                       |         |        984 | 
+-------------------------------------------+---------+------------+ 
|                                           |         |            | 
+-------------------------------------------+---------+------------+ 
| Net book value                            |         |            | 
+-------------------------------------------+---------+------------+ 
| At 31 December 2009                       |         |      7,695 | 
+-------------------------------------------+---------+------------+ 
| At 31 December 2008                       |         |      1,046 | 
+-------------------------------------------+---------+------------+ 
| At 8 February 2008                        |         |          - | 
+-------------------------------------------+---------+------------+ 
 
10)  INVENTORIES 
+-------------------------------------------+---------+---------+ 
|                                           |    2009 |    2008 | 
+-------------------------------------------+---------+---------+ 
|                                           |     GBP |     GBP | 
+-------------------------------------------+---------+---------+ 
| Raw materials and consumables             |  38,896 |  19,175 | 
+-------------------------------------------+---------+---------+ 
 
The inventory expensed to cost of sales in the year is GBP32,044 (period to 31 
December 2008: GBP31,582) and there has been no write off of stock in the year. 
 
11)  TRADE AND OTHER RECEIVABLES 
+-------------------------------------------+---------+---------+ 
|                                           |    2009 |    2008 | 
+-------------------------------------------+---------+---------+ 
|                                           |     GBP |     GBP | 
+-------------------------------------------+---------+---------+ 
| Trade receivables                         |  12,999 |  21,382 | 
+-------------------------------------------+---------+---------+ 
| Other receivables                         | 154,389 |   5,065 | 
+-------------------------------------------+---------+---------+ 
| Prepayments and accrued income            |   2,054 |  13,755 | 
+-------------------------------------------+---------+---------+ 
|                                           | 169,442 |  40,202 | 
+-------------------------------------------+---------+---------+ 
 
The Directors consider that the carrying amount of trade and other receivables 
approximates to their fair value. 
 
No provisions are held against receivables and no amounts past due have been 
impaired. 
 
Included in other receivables is an amount of GBP143,590 owed by Oxford 
Nutrascience Group plc, see note 18 for further information. 
 
12)  RISK MANAGEMENT OF FINANCIAL ASSETS AND LIABILITIES 
 
The Company's activities expose it to a variety of financial risks: market risk 
(specifically interest rate risk), credit risk and liquidity risk.  The 
Company's overall risk management programme focuses on the unpredictability of 
financial markets and seeks to minimise potential adverse effects on the 
Company's financial performance. 
 
The management of these risks is vested in the Board of Directors.  The policies 
for managing each of these risks are summarise below: 
 
Management of market risk 
 
i) Interest rate risk 
As the Company has no significant borrowings the risk is limited to the 
potential reduction in interest received on cash surpluses held.  Interest rate 
risk is managed in accordance with the liquidity requirement of the Company, 
with a minimum of 30 per cent. of its cash surpluses held within an instant 
access account, which has a variable interest rate attributable to it, to ensure 
that sufficient funds are available to cover the working capital requirements of 
the Company. 
 
Interest rate sensitivity 
The principal impact to the Company is the result of interest-bearing cash and 
cash equivalent balances held as set out below: 
 
+----------------+-------+----------+---------+---------+----------+---------+ 
|                |            2009            |            2008              | 
+----------------+----------------------------+------------------------------+ 
|                | Fixed | Floating |   Total |   Fixed | Floating |   Total | 
|                |  rate |     rate |         |    rate |     rate |         | 
+----------------+-------+----------+---------+---------+----------+---------+ 
|                |   GBP |      GBP |     GBP |     GBP |      GBP |     GBP | 
+----------------+-------+----------+---------+---------+----------+---------+ 
| Cash and cash  |     - |  637,725 | 637,725 | 475,000 |  513,967 | 988,967 | 
| equivalents    |       |          |         |         |          |         | 
+----------------+-------+----------+---------+---------+----------+---------+ 
 
At 31 December 2009, the impact of a 10 per cent. increase or decrease in 
interest rates would have decreased/increased loss for the year by GBP638 
(period to 31 December 2008: GBP514) as a result of higher/lower interest 
received on floating rate cash deposits. 
 
Management of credit risk 
 
The Company is exposed to credit risk from its operating activities, it 
principally arises from account receivables and to a lesser extent from short 
term bank deposits.   The Company seeks to minimse this risk by only depositing 
funds with banks with a minimum rating of 'A', and by entering into formal 
contracts with its major customers, as well as using credit checks. 
 
The maximum exposure to credit risk on the Company's financial assets is 
represented by their carrying amounts as outlined in the categorisation of 
financial instruments table above. 
 
The Company does not consider that any changes in fair value of financial assets 
or liabilities in the year are attributable to credit risk. 
 
+---------------------------------------+-----------+----------+ 
|                                       |      2009 |     2008 | 
+---------------------------------------+-----------+----------+ 
| The Company                           |    GBP000 |   GBP000 | 
+---------------------------------------+-----------+----------+ 
| Cash and cash equivalents             |           |          | 
+---------------------------------------+-----------+----------+ 
| AA                                    |   256,399 |  450,100 | 
+---------------------------------------+-----------+----------+ 
| A                                     |   381,326 |  538,867 | 
+---------------------------------------+-----------+----------+ 
|                                       |   637,725 |  988,967 | 
+---------------------------------------+-----------+----------+ 
| Trade receivables                     |           |          | 
+---------------------------------------+-----------+----------+ 
| Current                               |     5,363 |    4,058 | 
+---------------------------------------+-----------+----------+ 
| 1 month - 6 months old                |     7,636 |   17,324 | 
+---------------------------------------+-----------+----------+ 
|                                       |    12,999 |   21,382 | 
+---------------------------------------+-----------+----------+ 
 
Management of liquidity risk 
 
The Company seeks to manage liquidity risk to ensure that sufficient liquidity 
is available to meet foreseeable needs and to invest cash assets safely and 
profitably. The Company deems there is sufficient liquidity for the foreseeable 
future. 
 
The Company had cash and cash equivalents at 31 December 2009 of GBP637,725 (31 
December 2008: GBP988,967). 
 
As at 31 December 2009 all financial assets and liabilities mature for payment 
within one year. 
 
Capital risk management 
The Company manages its capital to ensure that the Company will be able to 
continue as a going concern while maximising the return to stakeholders.  The 
Company's overall strategy remains unchanged from 2008 to minimise costs and 
liquidity risk. 
 
The capital structure of the Company consists of equity attributable to equity 
holders of the parent, comprising issued capital, as disclosed in note 14 and 
reserves and retained earnings as disclosed in the Statement of Changes in 
Equity. 
 
The Company is exposed to a number of risks through its normal operations, the 
most significant of which are market, credit and liquidity risks. The management 
of these risks is vested with the Board of Directors. 
 
Categorisation of financial instruments 
 
+----------------------+--+-------------+-------------+----------+ 
| Financial            |                |             |          | 
| assets/(liabilities) |                |             |          | 
+----------------------+----------------+-------------+----------+ 
|                      |  |   Loans and |   Financial |    Total | 
|                      |  | receivables | liabilities |          | 
|                      |  |             |          at |          | 
|                      |  |             |   amortised |          | 
|                      |  |             |        cost |          | 
+----------------------+--+-------------+-------------+----------+ 
|                      |  |         GBP |         GBP |      GBP | 
+----------------------+--+-------------+-------------+----------+ 
| At 31 December 2009  |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| Trade and other      |  |     167,388 |           - |  167,388 | 
| receivables          |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| Cash and cash        |  |     637,725 |           - |  637,725 | 
| equivalents          |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| Trade and other      |  |           - |    (53,206) | (53,206) | 
| payables             |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| TOTAL                |  |     805,113 |    (53,206) |  751,907 | 
+----------------------+--+-------------+-------------+----------+ 
|                      |  |   Loans and |   Financial |    Total | 
|                      |  | receivables | liabilities |          | 
|                      |  |             |          at |          | 
|                      |  |             |   amortised |          | 
|                      |  |             |        cost |          | 
+----------------------+--+-------------+-------------+----------+ 
|                      |  |         GBP |         GBP |      GBP | 
+----------------------+--+-------------+-------------+----------+ 
| At 31 December 2008  |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| Trade and other      |  |      26,447 |           - |   26,447 | 
| receivables          |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| Cash and cash        |  |     988,967 |           - |  988,967 | 
| equivalents          |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| Trade and other      |  |           - |    (39,908) | (39,908) | 
| payables             |  |             |             |          | 
+----------------------+--+-------------+-------------+----------+ 
| TOTAL                |  |   1,015,414 |    (39,908) |  975,506 | 
+----------------------+--+-------------+-------------+----------+ 
 
The Company had no financial instruments measured at fair value through profit 
and loss. 
 
13)  TRADE AND OTHER PAYABLES 
+---------------------------------------------+--------+--------+ 
|                                             |   2009 |   2008 | 
+---------------------------------------------+--------+--------+ 
|                                             |    GBP |    GBP | 
+---------------------------------------------+--------+--------+ 
| Trade payables                              | 48,297 | 36,977 | 
+---------------------------------------------+--------+--------+ 
| Other payables                              |  1,462 |    473 | 
+---------------------------------------------+--------+--------+ 
| Taxes and social security                   |  3,447 |  2,458 | 
+---------------------------------------------+--------+--------+ 
| Accruals                                    |  5,735 |    700 | 
+---------------------------------------------+--------+--------+ 
|                                             | 58,941 | 40,608 | 
+---------------------------------------------+--------+--------+ 
 
The Directors consider that the carrying amount of trade and other payables 
approximates to their fair value. 
 
14)  SHARE CAPITAL 
 
+-----------------------+------------+---------------+----------+----------+---------+ 
|                       |   Ordinary |      Ordinary | Ordinary | Ordinary |   Total | 
|                       |     shares |      A shares |   shares | A shares |         | 
|                       |         of |      of 0.01p |    of 1p | of 0.01p |         | 
|                       |    1p each |          each |     each |     each |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
|                       |     Number |        Number |      GBP |      GBP |     GBP | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Authorised:           |            |               |          |          |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| At 8 February 2008    |          - |             - |        - |        - |       - | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Authorised ordinary   | 49,970,000 |             - |  499,700 |        - | 499,700 | 
| shares                |            |               |          |          |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Authorised ordinary A |          - |     3,000,000 |        - |      300 |     300 | 
| shares                |            |               |          |          |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| At 31 December 2008   | 49,970,000 |     3,000,000 |  499,700 |      300 | 500,000 | 
| and 31 December 2009  |            |               |          |          |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Share conversion      |     30,000 |   (3,000,000) |      300 |    (300) |       - | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| At 31 December 2009   | 50,000,000 |             - |  500,000 |        - | 500,000 | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Allotted, issued and  |            |               |          |          |         | 
| fully paid shares:    |            |               |          |          |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| At 8 February 2008    |          - |             - |        - |        - |       - | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Proceeds from issue   | 13,046,666 |             - |  130,467 |        - | 130,467 | 
| of ordinary shares    |            |               |          |          |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Proceeds from issue   |          - |     3,000,000 |        - |      300 |     300 | 
| of ordinary A shares  |            |               |          |          |         | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| At 31 December 2008   | 13,406,666 |     3,000,000 |  130,467 |      300 | 130,767 | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Share issue           |          - |   297,000,000 |        - |   29,700 |  29,700 | 
+-----------------------+------------+---------------+----------+----------+---------+ 
| Share conversion      |  3,000,000 | (300,000,000) |   30,000 | (30,000) |       - | 
+-----------------------+------------+---------------+----------+----------+---------+ 
|                       | 16,406,666 |             - |  160,467 |        - | 160,467 | 
+-----------------------+------------+---------------+----------+----------+---------+ 
 
On 26 October 2009 297,000,000 ordinary A shares of 0.01p each were issued to 
the holders of the ordinary A shares on the basis of 99 new ordinary A shares 
for every 1 ordinary A share held.  GBP29,700  from the share premium reserve 
was capitalised to pay for the issue, see note 15. 
 
On 27 October 2009 a resolution was passed to consolidate and convert all 
ordinary A shares to ordinary shares on the basis of 1 ordinary share for every 
100 ordinary A shares held. 
 
15)  SHARE PREMIUM 
 
+--------------------------------------------------+----------+ 
|                                                  |    Share | 
|                                                  |  Premium | 
+--------------------------------------------------+----------+ 
|                                                  |      GBP | 
+--------------------------------------------------+----------+ 
| At 8 February 2008                               |        - | 
+--------------------------------------------------+----------+ 
| Premium on issue of shares                       |  984,533 | 
+--------------------------------------------------+----------+ 
| At 31 December 2008                              |  984,533 | 
+--------------------------------------------------+----------+ 
| Capitalisation on issue of new ordinary A shares | (29,700) | 
+--------------------------------------------------+----------+ 
| At 31 December 2009                              |  954,833 | 
+--------------------------------------------------+----------+ 
 
16)  COMMITMENTS 
 
Operating lease commitments 
The Group leases premises under non-cancellable operating lease agreements.  The 
future aggregate minimum lease and service charge payments under non-cancellable 
operating leases are as follows: 
 
+--------------------------------------------+----------+----------+ 
|                                            |       31 |       31 | 
|                                            | December | December | 
|                                            |     2009 |     2008 | 
+--------------------------------------------+----------+----------+ 
|                                            |      GBP |      GBP | 
+--------------------------------------------+----------+----------+ 
| Land and buildings:                        |          |          | 
+--------------------------------------------+----------+----------+ 
| Expiring in less than one year             |      680 |     2480 | 
+--------------------------------------------+----------+----------+ 
| Expiring in one to five years              |        - |      600 | 
+--------------------------------------------+----------+----------+ 
|                                            |      680 |    3,080 | 
+--------------------------------------------+----------+----------+ 
 
17)  RELATED PARTY TRANSACTIONS 
 
Transactions with Key Management Personnel 
 
The Company's key management personnel comprise only the Directors of the 
Company. 
 
During the year the Company entered into the following transactions in which the 
Directors had an interest: 
 
Directors' remuneration: 
Remuneration received by the Directors from the Company is set out below: 
 
+----------------------------+----------+--------------+---------+--------+ 
|                            |               2009                |   2008 | 
+----------------------------+-----------------------------------+--------+ 
| Short-term employment      | Salaries |   Employer's |   Total |  Total | 
| benefits                   |   & fees |     national |         |        | 
|                            |          |    insurance |         |        | 
|                            |          | contribution |         |        | 
+----------------------------+----------+--------------+---------+--------+ 
|                            |   GBP000 |       GBP000 |  GBP000 | GBP000 | 
+----------------------------+----------+--------------+---------+--------+ 
| Nigel Theobald             |  105,915 |       10,798 | 116,713 | 63,521 | 
+----------------------------+----------+--------------+---------+--------+ 
| Marcelo Bravo              |        - |            - |       - |      - | 
+----------------------------+----------+--------------+---------+--------+ 
| Michael Bretherton         |        - |            - |       - |      - | 
+----------------------------+----------+--------------+---------+--------+ 
| David Norwood*             |        - |            - |       - |      - | 
+----------------------------+----------+--------------+---------+--------+ 
*David Norwood resigned on 31 December 2008 
 
18)  EVENTS AFTER THE BALANCE SHEET DATE 
 
On 27 January 2010, Oxford Nutrascience Group PLC acquired 100 per cent of the 
issued share capital of the Company by issue of 401,164,650 new ordinary shares 
at 1.6 pence per share, which valued the Company at GBP6,418,666. This 
transaction was completed as part of a re-organisation to admit the Group to 
trading on AIM and to raise gross proceeds of GBP1,100,000 under a placing of 
new shares at 1.75 pence per share.  The placing and admission to AIM was 
completed on 12 February 2010. 
 
19)  CASH AND CASH EQUIVALENTS 
 
Cash and cash equivalent consist of cash in hand and balances with banks, and 
cash held on short term deposit.  Cash and cash equivalents included in the 
statement of cash flows comprise the following amounts in the statement of 
financial position: 
 
+--------------------------------------+-----------+-----------+ 
|                                      |        31 |        31 | 
|                                      |  December |  December | 
|                                      |      2009 |      2008 | 
+--------------------------------------+-----------+-----------+ 
|                                      |       GBP |       GBP | 
+--------------------------------------+-----------+-----------+ 
| Cash in hand and balances with bank  |   637,725 |   513,967 | 
+--------------------------------------+-----------+-----------+ 
| Cash held on short-term deposits     |         - |   475,000 | 
+--------------------------------------+-----------+-----------+ 
| At 31 December 2008                  |   637,725 |   988,967 | 
+--------------------------------------+-----------+-----------+ 
 
20)  ULTIMATE CONTROLLING PARTY 
 
At 31 December 2009 the Directors' do not believe that there was an ultimate 
controlling party. 
 
On 27 January 2010 Oxford Nutrascience Group plc acquired the entire issued 
share capital of the Company and is now regarded by the Directors as the 
Company's parent and ultimate controlling party. 
 
21) RECONCILIATION FROM UK GAAP TO IFRS 
 
There were no reconciling items between the UK GAAP profit and loss account and 
the IFRS statement of comprehensive income for the Company in the period to 31 
December 2008. 
 
There were no reconciling items between the balance sheet and the IFRS Statement 
of Financial Position for the Company at 31 December 2008. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 FR FMGGKZDNGGZM 
 

Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Oxford Nutrascience Charts.
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Oxford Nutrascience Charts.